Exact Sciences Corp [EXAS] stock is trading at $55.98, up 1.54%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EXAS shares have gain 10.98% over the last week, with a monthly amount drifted -5.76%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Exact Sciences Corp [NASDAQ: EXAS] stock has seen the most recent analyst activity on January 23, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $70. Previously, Wells Fargo started tracking the stock with Overweight rating on August 28, 2024, and set its price target to $75. On June 27, 2024, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $70 on the stock. The Benchmark Company upgraded its rating to a Buy but $91 remained the price target by the analyst firm on January 02, 2024. Guggenheim started tracking with a Buy rating for this stock on December 14, 2023, and assigned it a price target of $90. In a note dated December 13, 2023, Wolfe Research initiated an Outperform rating and provided a target price of $95 on this stock.
Exact Sciences Corp [EXAS] stock has fluctuated between $40.62 and $79.62 over the past year. Currently, Wall Street analysts expect the stock to reach $77 within the next 12 months. Exact Sciences Corp [NASDAQ: EXAS] shares were valued at $55.98 at the most recent close of the market. An investor can expect a potential return of 37.55% based on the average EXAS price forecast.
Analyzing the EXAS fundamentals
Exact Sciences Corp [NASDAQ:EXAS] reported sales of 2.69B for the trailing twelve months, which represents a growth of 12.78%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.08%, and Net Profit Margin reading is -0.08%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.07 and Total Capital is -0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.86.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 54.39 points at the first support level, and at 52.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 56.78, and for the 2nd resistance point, it is at 57.59.
Ratios To Look Out For
For context, Exact Sciences Corp’s Current Ratio is 2.12. As well, the Quick Ratio is 1.93, while the Cash Ratio is 0.81. Considering the valuation of this stock, the price to sales ratio is 3.85, the price to book ratio is 3.23.
Transactions by insiders
Recent insider trading involved Conroy Kevin T, President and CEO, that happened on Nov 13 ’24 when 19500.0 shares were purchased. EVP, GM, Precision Oncology, Baranick Brian completed a deal on Oct 08 ’24 to sell 929.0 shares. Meanwhile, Officer Baranick Brian bought 929.0 shares on Oct 08 ’24.
